The MarketWatch News Department was not involved in the creation of this content. -- Catumaxomab Is the Only Approved Drug Therapy for Malignant Ascites, a Rare and Debilitating Complication of ...
BioVie’s stock has moved up considerably over the past 9 months in light of promising Alzheimer’s data. BioVie Day and full Phase 2 Parkinson’s trial results are scheduled for this month. BioVie has ...
Please provide your email address to receive an email when new articles are posted on . The FDA has granted orphan drug designation to Ocelot Bio’s OCE-205, a mixed vasopression 1a receptor ...
The "Ascites Market - A Global and Regional Analysis: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The ascites ...
DUBLIN, June 23, 2021 /PRNewswire/ -- The "Malignant Ascites Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 ...
NEW YORK, Nov. 15, 2024 /PRNewswire/ -- Martin Pharmaceuticals, a clinical-stage pharmaceutical company targeting complications of advanced liver disease, today announced that results from its DREAM ...
Ascites is a common complication of cirrhosis of the liver. Build-up of fluid causes the abdomen to swell and may lead to discomfort, difficulty breathing, fatigue, nausea and poor appetite. Treatment ...
BASILDON, England--(BUSINESS WIRE)--Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has ...
Final analysis of SCORES, a phase III randomized, double-blinded, placebo-controlled study of suvemcitug combined with chemotherapy for platinum-resistant ovarian cancer. This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results